Akari Therapeutics, Plc (NASDAQ:AKTX) Sees Large Growth in Short Interest

Akari Therapeutics, Plc (NASDAQ:AKTX) was the target of a large growth in short interest in December. As of December 15th, there was short interest totalling 74,100 shares, a growth of 30.2% from the November 30th total of 56,900 shares. Based on an average daily trading volume, of 44,100 shares, the short-interest ratio is presently 1.7 days. Approximately 0.6% of the shares of the stock are sold short.

Analysts Set New Price Targets

Separately, StockNews.com assumed coverage on Akari Therapeutics in a research report on Saturday. They set a “sell” rating for the company.

Akari Therapeutics Stock Performance

Shares of Akari Therapeutics stock opened at $0.97 on Friday. The business has a 50-day moving average price of $1.63 and a 200-day moving average price of $2.73. Akari Therapeutics has a twelve month low of $0.90 and a twelve month high of $4.40.

About Akari Therapeutics

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration.